Novacyt hails positive UK trial data for Covid-19 test


Paris-based diagnostics group Novacyt said encouraging interim data had been reported from an ongoing clinical trial in care homes that was assessing the accuracy of its Covid-19 test.

Queen Mary University of London had completed an interim review of the performance of the company's near-patient testing system that involved an analysis of over 4,000 samples from care home residents and staff.

The clinical accuracy of Novacyt's system was found to have greater than 99% clinical sensitivity and specificity when compared to a standard central laboratory system.

'These data demonstrate the reliability and accuracy of Novacyt's NPT system,' the company said.

'In addition, mid-nose nasal swabs were found to be effective and well tolerated compared to the more invasive nasopharyngeal swabs.'

Novacyt also announced the launch of a new product to improve the workflow efficiency of its near-patient testing COVID-19 test.

At 9:36am: (LON:NCYT) Novacyt S.A share price was 0p at 897p

Related content

Novacyt products included in UK testing framework for Covid-19 variants

Diagnostics group Novacyt said its Covid-19 testing products had been included in a UK framework for identifying variants of the disease.

The company's SARS-CoV-2 polymerase...

Mon, 17/05/2021 - 08:06

Novacyt shock means investors should get out now


A profit warning on 9 April from specialist clinical diagnostics firm Novacyt (NCYT:AIM) is a major turning point for how we view the stock....

Thu, 15/04/2021 - 00:00

Novacyt hails progress on Covid-19 testing efforts

Paris-based diagnostics group Novacyt said Queen Mary University of London had completed clinical trial using its rapid testing platforms for Covid-19 in care homes.


Wed, 24/02/2021 - 08:50

The best performing stocks of 2020

After an extraordinary year we look back at some of the top performers in different size categories from the heavyweights all the way down to...

Wed, 23/12/2020 - 00:00

GlaxoSmithKline vaccine delay and Novacyt's new virus strain test


GlaxoSmithKline (GSK) £14.00

Gain to date: 6%
Original entry point: Buy at £13.21, 5 November 2020

Novacyt (NCYT:AIM) 870.2p


Thu, 17/12/2020 - 00:00